Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend Its Reporting Obligations

GlobeNewswireMay 10 04:10

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

GlobeNewswireMar 26 20:00

Ayala Completes Patient Enrollment for Pivotal Desmoid Tumor Study

Investing.com Feb 20 23:32

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

GlobeNewswireFeb 20 21:00

Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating

MT NewswiresFeb 7 21:53

Advaxis Announces Definitive Agreement With Ayala Pharmaceuticals

TipRanksFeb 7 17:17